Fairvalue-Calculator Fairvalue-Calculator
EN DE

Seouleaguer Co (043710) Fair Value & Analysis

Consumer Non-Cyclicals · KR · Market cap 68.2B KRW

Price3,740 KRW
Fair Value4,843 KRW
Upside+29.5%
Quality93/100
Evidence: Low Range 3,633 KRW – 6,054 KRW

Fair value as of: Jun 24, 2026

Analysis

Seouleaguer Co (043710) currently trades at 3,740 KRW, while our model-based Fair Value estimate is 4,843 KRW — implying the stock looks roughly 29.5% undervalued today. We read business quality at 93/100 (high quality), in the Consumer Non-Cyclicals sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Seouleaguer Co., Ltd., a medical beauty care platform company, provides hospital management support services in South Korea. The company was formerly known as Rocketmobile Co., Ltd. and changed its name to Seouleaguer Co., Ltd. in July 2016. Seouleaguer Co., Ltd. was founded in 1991 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Sierra Madre Gold and Silver Ltd (SM) +58% PGOLD (PGOLD) +58% RRHI (RRHI) -2% SEVN (SEVN) +6% COSCO (COSCO) +693% Curexo Inc (060280) -82%

Frequently asked questions

Is Seouleaguer Co (043710) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 4,843 KRW versus a price of 3,740 KRW — about +30% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 043710?
Our 21-model fair value for Seouleaguer Co is 4,843 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 3,740 KRW.
What is the quality score of 043710?
Seouleaguer Co has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.